A Clinically Translatable Ternary Platinum(IV) Prodrug for Synergistically Reversing Drug Resistance
Journal of Medicinal Chemistry · 23.03.2023 · 66 (6) · 4045-4058
DOI: 10.1021/acs.jmedchem.2c01924 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 10.03.2023. Verfasst von Ying Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hengyang Medical School, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study & School of Pharmaceutical Science, Univers…. Hauptthemen laut MEDLINE: Prodrugs, Antineoplastic Agents. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: State Key Laboratory of Polymer Physics and Chemistry, Natural Science Foundation of Hunan Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Scalable production of a clinically translatable formulation with enhanced therapeutic efficacy against cisplatin-resistant tumors without the use of any clinically unapproved reagents and additional manipulation remains a challenge. For this purpose, we report herein the construction of TPP-Pt-acetal-CA based on all commercially available, clinically approved reagents consisting of a cinnamaldehyde (CA) unit for reactive oxygen species generation, a mitochondrially targeted triphenylphosphonium (TPP)-modified Pt(IV) moiety for mitochondrial dysfunction, and an intracellular acidic pH-cleavable acetal link between these two moieties. The resulting self-assembled, stabilized TPP-Pt-acetal-CA nanoparticles mediated an IC50 value approximately 6-fold lower than that of cisplatin in A549/DDP cells and a tumor weight reduction 3.6-fold greater than that of cisplatin in A549/DDP tumor-bearing BALB/c mice with insignificant systematic toxicity due to the synergistic mitochondrial dysfunction and markedly amplified oxidative stress. Therefore, this study presents the first example of a clinically translatable Pt(IV) prodrug with enhanced efficiency for synergistically reversing drug resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hengyang Medical School, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study & School of Pharmaceutical Science, University of South China, Hengyang 421001, China.
- College of Life Science, Hengyang Normal University, Hengyang 421001, China.
ORCID-Profile: Cui-Yun Yu, Hua Wei
Förderung
- State Key Laboratory of Polymer Physics and Chemistry
- Natural Science Foundation of Hunan Province
- National Natural Science Foundation of China
- Key Research and Development Program of Hunan Province of China
Zitieren
APA
Liu, Y., Wang, D., Liu, H., Liu, L., Li, S., Zhou, Z., Lu, L., Liu, X., He, L., He, D., Yu, C. Y., & Wei, H. (2023). A Clinically Translatable Ternary Platinum(IV) Prodrug for Synergistically Reversing Drug Resistance. Journal of Medicinal Chemistry, 66(6), 4045-4058. https://doi.org/10.1021/acs.jmedchem.2c01924
Vancouver
Liu Y, Wang D, Liu H, Liu L, Li S, Zhou Z, et al. A Clinically Translatable Ternary Platinum(IV) Prodrug for Synergistically Reversing Drug Resistance. Journal of Medicinal Chemistry. 2023;66(6):4045-4058. doi:10.1021/acs.jmedchem.2c01924
BibTeX
@article{Liu2023,
author = {Liu, Ying and Wang, Dun and Liu, Hongbing and Liu, Li and Li, Shuang and Zhou, Zongtao and Lu, Linyin and Liu, Xuyue and He, Lifang and He, Dongxiu and Yu, Cui-Yun and Wei, Hua},
title = {A Clinically Translatable Ternary Platinum(IV) Prodrug for Synergistically Reversing Drug Resistance},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {6},
pages = {4045--4058},
doi = {10.1021/acs.jmedchem.2c01924}
}
EUVIMED